报价延迟最少15分钟:2025/07/21 18:54 EDT
盘后时段
|
||||
|
10.86 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.01/--
|
|
企业价值
925.36M
|
| 资产负债 |
|
每股账面净值
3.53
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
9.04M
|
|
每股收益
0.08
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 18:54 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others. |
